No Data
No Data
OncoSil Medical Discloses Shareholder Concentration
OncoSil Medical Ltd has announced that a significant majority, roughly 99.29%, of its securities are concentrated within a small group of holders, each owning upward of 100,000 units.
OncoSil Medical Treats Fifth Pancreatic Cancer Patient With Proprietary Device
OncoSil Medical (ASX:OSL) treated the fifth patient in the PANCOSIL trial with its proprietary OncoSil device, the pancreatic cancer treatment device company said in a Tuesday filing with the Australi
Oncosil Medical Treats 200th Pancreatic Cancer Patient With Proprietary Device
Oncosil Medical (ASX:OSL) completed the treatment of 200 patients of pancreatic cancer with the OncoSil device, according to a Monday filing with the Australian bourse. The OncoSil device is a disposa
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial
OncoSil Medical (ASX:OSL) treated two more patients in the Netherlands using its implantable pancreatic cancer device, according to an April 17 filing with the Australian bourse. The treatment is part
OncoSil Medical Treats First Commercial Patient in Turkey With Implantable Pancreatic Cancer Device
OncoSil Medical (ASX:OSL) treated the first commercial patient in Turkey with its implantable OncoSil pancreatic cancer therapy device, according to a Tuesday filing with the Australian Securities Exc
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study
OncoSil Medical (ASX:OSL) on Friday announced the first patient treatment in the UK that utilized its pancreatic cancer device for its TRIPP-FXX clinical study. The study aims to assess the safety and
No Data